OrsoBio key facts
- Operator of a clinical-stage biopharmaceutical company intended to develop therapies for organ dysfunction.
- OrsoBio’s last known valuation is $310.0M.
- It has raised $166.6M across 2 recorded rounds; the latest was Early Stage VC ($40.0M) in Aug 2024.
- Notable investors include Samsara BioCapital, Longitude Capital, Woodline Partners, Ascenta Capital, Eli Lilly — 8 tracked in total.
- OrsoBio has filed 2 Form Ds with the SEC since 2023, most recently Aug 2024 ($40.0M sold to 7 investors).
- Status: Privately Held (backing).
- ·Watch OrsoBio: the Monday email on marks, rounds and moves
OrsoBio funding rounds
2 roundsOrsoBio valuation
OrsoBio's last known valuation is $310 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
How much has OrsoBio raised?
OrsoBio has raised $167 million in total; 2 of its rounds are on record. The largest on record was an $84.6 million later-stage round in Oct 2023; the most recent was a $40 million early-stage round in Aug 2024.
OrsoBio has filed 2 Form Ds with the SEC since 2023, most recently in Aug 2024 ($40 million sold to 7 investors).
OrsoBio investors
8 investors are on record for OrsoBio, including Samsara BioCapital, Longitude Capital, Woodline Partners and Ascenta Capital. The early-stage round in Aug 2024 drew 7 investors.
About OrsoBio
Operator of a clinical-stage biopharmaceutical company intended to develop therapies for organ dysfunction. The company develops therapies to treat obesity and obesity-associated disorders, including type 2 diabetes, MASH, and severe dyslipidemia, enabling patients to boost the energy metabolism of their bodies.
- Sector
- Healthcare
- HQ
- Menlo Park, CA, United States
- Founded
- 2020
- Employees
- 15
- Website
- orsobio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
OrsoBio’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.